−0.94USD
−234.63 MUSD
130.00 KUSD
117.74 M
About Lyell Immunopharma, Inc.
Sector
Industry
CEO
Lynn Seely
Website
Headquarters
South San Francisco
Employees (FY)
224
Founded
2018
ISIN
US55083R1041
FIGI
BBG00RNXFN14
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of LYEL is 2.33 USD — it has decreased by 2.10% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Lyell Immunopharma, Inc. stocks are traded under the ticker LYEL.
Lyell Immunopharma, Inc. is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
LYEL stock is 6.86% volatile and has beta coefficient of 2.61. Check out the list of the most volatile stocks — is Lyell Immunopharma, Inc. there?
One year price forecast for Lyell Immunopharma, Inc. has a max estimate of 9.00 USD and a min estimate of 5.00 USD.
LYEL earnings for the last quarter are −0.20 USD whereas the estimation was −0.24 USD which accounts for 17.36% surprise. Estimated earnings for the next quarter are −0.23 USD. See more details about Lyell Immunopharma, Inc. earnings.
Lyell Immunopharma, Inc. revenue for the last quarter amounts to 25.00 K USD despite the estimated figure of 6.25 K USD. In the next quarter revenue is expected to reach 3.25 K USD.
Yes, you can track Lyell Immunopharma, Inc. financials in yearly and quarterly reports right on TradingView.
LYEL stock has fallen by 5.28% compared to the previous week, the month change is a 12.56% rise, over the last year Lyell Immunopharma, Inc. has showed a 1.69% decrease.
LYEL net income for the last quarter is −52.93 M USD, while the quarter before that showed −50.85 M USD of net income which accounts for −4.08% change. Track more Lyell Immunopharma, Inc. financial stats to get the full picture.
Today Lyell Immunopharma, Inc. has the market capitalization of 604.75 M, it has increased by 5.29% over the last week.
No, LYEL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, LYEL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Lyell Immunopharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 224.00 employees. See our rating of the largest employees — is Lyell Immunopharma, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Lyell Immunopharma, Inc. technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Lyell Immunopharma, Inc. stock shows the sell signal. See more of Lyell Immunopharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Lyell Immunopharma, Inc. future price: according to them, LYEL price has a max estimate of 9.00 USD and a min estimate of 5.00 USD. Read a more detailed Lyell Immunopharma, Inc. forecast: see what analysts think of Lyell Immunopharma, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Lyell Immunopharma, Inc. EBITDA is −231.00 M USD, and current EBITDA margin is −177.29 K%. See more stats in Lyell Immunopharma, Inc. financial statements.